FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Trial Status: Active
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
- Inclusion Criteria: 1. Diagnosis of the following, as per Regimen Cohort: 1A. Regimen A: FT500 Monotherapy (Dose Escalation and Expansion): An advanced solid tumor malignancy, including lymphoma, in a subject who has failed or refused available FDA-approved therapies and is now a candidate for salvage therapy. 1B. Regimen B: FT500 + ICI (Dose Escalation): An advanced solid tumor malignancy, including lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab, pembrolizumab or atezolizumab), in a subject who has also failed or refused other available approved therapies and is now a candidate for salvage therapy. 1C. Regimen B: FT500 + ICI (Dose Expansion): An advanced solid tumor malignancy, including lymphomas, in a subject who is currently receiving nivolumab, pembrolizumab or atezolizumab per USPI, with disease progression on the ICI. 2. Provision of signed and dated ICF. 3. Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start of lympho-conditioning and within 28 days prior to Day 1. 4. Stated willingness to comply with study procedures and duration. 5. Provision of signed and dated ICF to agree to participate, at time of withdrawal or completion of this study, in Fate Therapeutics' long-term, non-interventional, observation study, FT-003. Exclusion Criteria: All Subjects: 1. Females of reproductive potential who are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from Screening through the end of the study. 2. ECOG performance status ≥ 2. 3. Evidence of insufficient organ function as determined by any one of the following: 1. Neutrophils <1000/µL or platelets <75,000/µL. 2. Estimated creatinine clearance <50 mL/minute (Cockcroft-gault). 3. Total bilirubin >2 x upper limit normal (ULN) with the exception of subjects with Gilbert's Syndrome or known liver metastases. 4. Aspartate aminotransferase (AST) >3 x ULN, or alanine aminotransferase (ALT) >3 x ULN. For subjects with known liver metastases, AST or ALT >5 x ULN. 5. Oxygen saturation <90% on room air; pulmonary function tests (PFTs) required if symptomatic or prior known impairment - subject will be excluded if diffusing capacity of the lungs for carbon monoxide (DLCO) or forced expiratory volume 1 (FEV1) is <50% of predicted for height and age. 6. Left ventricular ejection fraction (LVEF) <40% (eg by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan). 4. Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation) within 2 weeks prior to Day 1. Subjects in Regimen B currently taking an ICI must interrupt ICI dosing at least 2 weeks prior to Day 1. 5. CNS metastases that have not been treated; or treated CNS metastases that have not been stable for at least 6 months. 6. Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first study medication; or the presence of unstable angina or congestive heart failure of New York Heart Association grade 2 or higher. 7. Currently receiving or likely to require systemic immunosuppressive therapy (eg, prednisone >5 mg daily) for any reason from Day -7 to Day 29. 8. Uncontrolled infections. 9. Known allergy to the following FT500 components: Albumin (Human) or DMSO. 10. Presence of any medical or social issues that are likely to interfere with study conduct, or may cause increased risk to subject. Additional Exclusion Criteria for Regimen B: FT500 + ICI: 11. Subjects who experienced an ICI-related adverse reaction that resulted in discontinuation of the ICI. 12. Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's disease, ulcerative colitis), except for subjects with isolated vitiligo, atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and controlled thyroid disease. 13. Subjects who have received an allograft organ transplant.
University of California San Diego
University of Minnesota / Masonic Cancer Center
M D Anderson Cancer Center
Trial Phase Phase I
Trial Type Treatment
- Primary ID FT500-101
- Secondary IDs NCI-2019-01692
- Clinicaltrials.gov ID NCT03841110